CytomX Therapeutics Future Growth

How is CytomX Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

25.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:CTMX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	55	-36	-3	N/A	5
12/31/2024	55	-31	-33	-75	5
12/31/2023	60	-49	-48	-81	8
9/30/2022	72	-98	-142	-141	N/A
6/30/2022	73	-97	-138	-136	N/A
3/31/2022	71	-92	-132	-130	N/A
12/31/2021	70	-84	-121	-119	N/A
9/30/2021	66	-72	-107	-105	N/A
6/30/2021	66	-64	-103	-100	N/A
3/31/2021	67	-61	23	25	N/A
12/31/2020	100	-33	3	5	N/A
9/30/2020	92	-54	-9	-7	N/A
6/30/2020	85	-63	-8	-5	N/A
3/31/2020	78	-76	-154	-151	N/A
12/31/2019	57	-102	-144	-140	N/A
9/30/2019	61	-99	-144	-140	N/A
6/30/2019	62	-99	-126	-122	N/A
3/31/2019	75	-83	-105	-100	N/A
12/31/2018	60	-85	-79	-76	N/A
9/30/2018	75	-52	-28	-25	N/A
6/30/2018	87	-39	-27	-25	N/A
3/31/2018	74	-50	173	175	N/A
12/31/2017	72	-43	169	170	N/A
9/30/2017	51	-58	148	150	N/A
6/30/2017	30	-62	139	142	N/A
3/31/2017	24	-51	-18	-16	N/A
12/31/2016	15	-59	-4	-2	N/A
9/30/2016	11	-57	-14	-12	N/A
6/30/2016	9	-57	N/A	-6	N/A
3/31/2016	8	-50	N/A	-28	N/A

Earnings vs Savings Rate: CTMX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CTMX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CTMX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CTMX's revenue (1.7% per year) is forecast to grow slower than the US market (6.9% per year).

High Growth Revenue: CTMX's revenue (1.7% per year) is forecast to grow slower than 20% per year.

Future ROE: Insufficient data to determine if CTMX's Return on Equity is forecast to be high in 3 years time